Company news
Optiscan Imaging Limited news in 2026
Optiscan Imaging Limited's news releases, calls and decks from 2026, newest first.
Notification of cessation of securities - OIL
November 3, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
Optiscan Lodges U.S. FDA 510(k) Submission for InVue
October 4, 2026
Optiscan Lodges U.S. FDA 510(k) Submission for InForm
October 1, 2026
Change of Director's Interest Notice
September 15, 2026
Notification of cessation of securities - OIL
September 15, 2026
Application for quotation of securities - OIL
September 15, 2026
Significant Milestone Reached in ACL Digital Pathology Study
September 9, 2026
Change of Director's Interest Notice
September 9, 2026
Application for quotation of securities - OIL
September 9, 2026
Application for quotation of securities - OIL
September 8, 2026
Change of Director's Interest Notice
September 8, 2026
Change of Director's Interest Notice
September 8, 2026
Optiscan Initiates Head and Neck Cancer Study in the US
August 31, 2026
Preliminary Final Report
August 24, 2026
Appendix 4G & Corporate Governance Statement
August 24, 2026
2026 Annual Report
August 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 30, 2026
Optiscan Signs New Research Agreement for Breast Study
July 21, 2026
Head and Neck Study Progressing Ahead of Schedule
July 20, 2026
Optiscan Launches InSpecta Device for Veterinary Medicine
July 6, 2026
Halfway Mark Reached in Optiscan Breast Cancer Study
June 3, 2026
Second Anniversary of Optiscan and Mayo Clinic Agreement
May 31, 2026
Optiscan Receives $1.69m R&D Tax Refund
May 19, 2026
Optiscan Submits InSpecta FDA Dossier
March 30, 2026
Appendix 4D
February 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026